D.C. venture capital powerhouse Updata Partners will announce Thursday that it has raised $280.6 million in new funding.
Updata, whose portfolio includes Mashable and VideoBlocks, surpassed its goal for the Updata Partners V LP fund by about $5 million. As of April, it had reported raising $160 million to the Securities and Exchange Commission.
Could lab-grown bones replace tissue grafts and multiple painful surgeries? Nina Tandon is the CEO and co-founder of EpiBone, a Brooklyn-based biotech company that was chosen as one of the World Economic Forum’s 2015 Technology Pioneers. Tandon is also a World Economic Forum Young Scientist who will be speaking at the Annual Meeting of the New Champions in Tianjin, China, from June 26 to 28.
More women are studying science, technology, engineering and math at UC San Diego than at any other major college in the country, a recent analysis of enrollment has found.
The study conducted by BestColleges.com found that one in three women at UC San Diego graduate with a STEM degree, about three times the national average.
With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets, supporting the exploding supernova known as immuno-oncology.
The White House’s Cancer Moonshot 2020 is about much more than clinical research. Data, IT and patient engagement are major components.
Vice President Joe Biden on Wednesday is hosting the first National Cancer Moonshot Summit on the campus of Howard University in Washington, and lots of news is being made.
Vice President Joe Biden, who has personal experience of the heartbreak that cancer causes, has taken on humanity’s mortal enemy and aims to end the disease “as we know it.”
Businesses that set out to change the world might want to start in D.C.
That’s according to a new study from D.C.-based S&R Foundation’s Halcyon Incubator, which calls Washington the best U.S. city for “social entrepreneurs” — startup founders that attempt to solve social problems with scalable businesses, like the Georgetown grads tackling food-waste with their juicing company, Misfit Juicery.
The Biotechnology Innovation Organization today released the following statement in response to Democratic Presidential Candidate Hillary Clinton’s Initiative on Technology & Innovation:
“As one of America’s most innovative industries, biotechnology is tackling head-on the unrelenting scientific challenges inherent in the discovery, development and delivery of new, high-value healthcare, agricultural, industrial and environmental products.
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has been awarded a grant from the National Institute on Drug Abuse (“NIDA”) at the National Institutes of Health. The grant of approximately $1.0 million provides Cerecor with additional resources for the ongoing Phase 2 clinical trial for CERC-501, “A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.”
OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold at a price of $1.14375 per unit. The warrants will be exercisable beginning 90 days after the closing of the transaction, have an exercise price of $1.3125 per share of common stock and may be exercised for five years. The gross proceeds of the offering are $10.355 million. The Company will use the net proceeds, after payment of offering expenses to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse bioinformatics products and services, and for general corporate purposes.
